SCHEMBL1343544

SCHEMBL1343544

O=C(Oc1ccccn1)Sc1ccccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.44
EHMT1 Q9H9B1 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
ALDH1A1 P00352 6/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
PKM P14618 1/20 0.40
POLB P06746 2/20 0.39
RAB9A P51151 4/20 0.38
TSHR P16473 2/20 0.38
HPGD P15428 5/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
HSD17B10 Q99714 3/20 0.38
NPC1 O15118 3/20 0.38
KDM4E B2RXH2 1/20 0.38
ALOX15 P16050 1/20 0.38
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3872197 0.79 EHMT2 (0.44) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL2608495 0.79 LMNA (0.47) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL5633792 0.75 EHMT2 (0.56) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL450118 0.75 CES2 (0.46) ALDH1A1LMNAKMT2APKMPOLB
SCHEMBL11865903 0.75 CES2 (0.46) ALDH1A1LMNAKMT2APKMPOLB
SCHEMBL3075428 0.75 EHMT2 (0.56) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL4351146 0.75 LMNA (0.44) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL1479297 0.74 ALDH1A1 (0.55) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL101751 0.74 LMNA (0.48) ALDH1A1LMNAKMT2AMEN1PKM
SCHEMBL28960343 0.74 CES2 (0.45) ALDH1A1LMNAKMT2APKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117832456-A Preparation method of rare earth doped amorphous carbon coated silicon-carbon composite material 云南坤天新能源有限公司 2024-04-05 CN claimed
US-12570647-B2 Amino benzothiazole compounds for treatment of antibiotic resistant bacteria SAINT LOUIS UNIVERSITY (US) 2026-03-10 US disclosed
CN-114829543-B Aromatic isothiocyanates 默克专利股份有限公司 2024-09-10 CN disclosed
CN-117832456-A Preparation method of rare earth doped amorphous carbon coated silicon-carbon composite material 云南坤天新能源有限公司 2024-04-05 CN disclosed
US-20220267312-A1 AMINO BENZOTHIAZOLE COMPOUNDS FOR TREATMENT OF ANTIBIOTIC RESISTANT BACTERIA SAINT LOUIS UNIVERSITY (US) 2022-08-25 US disclosed
CN-114829543-A Aromatic isothiocyanates 默克专利股份有限公司 2022-07-29 CN disclosed
CN-114302872-A Aromatic isothiocyanates 默克专利股份有限公司 2022-04-08 CN disclosed
CN-113056288-A Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer 康奈尔大学 2021-06-29 CN disclosed
US-8062756-B2 Stepwise growth of oligomeric redox-active molecules on a surface without the use of protecting groups The Regents oft the University of California (US) 2011-11-22 US disclosed
WO-2011122815-A2 NOVEL QUINOXALINE DERIVATIVES DONG-A PHARM.CO.,LTD. (KR) 2011-10-06 WO disclosed
US-6011032-A Heterocyclic compounds for treating myocardial ischemia PIERRE FABRE MEDICAMENT (FR) 2000-01-04 US disclosed
EP-0934940-A1 CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF Japan Tobacco Inc. (JP) 1999-08-11 EP disclosed
US-5767256-A REACTING HYDROXYL GROUP-CONTAINING ACCEPTOR WITH DONOR SELECTED FROM O-PYRANOSYL AND O-FURANOSYL GLYCOSIDES HAVING PYRIDINE-CONTAINING LEAVING GROUPS HANESSIAN STEPHEN (CA) 1998-06-16 US disclosed
EP-0842174-A1 HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA PIERRE FABRE MEDICAMENT (FR) 1998-05-20 EP disclosed
WO-1997005134-A1 HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA PIERRE FABRE MEDICAMENT (FR) 1997-02-13 WO disclosed
WO-1995003316-A3 SOLUTION AND SOLID PHASE STEREOCONTROLLED GLYCOSIDATION HANESSIAN STEPHEN (CA) 1995-03-30 WO disclosed
WO-1995003316-A2 SOLUTION AND SOLID PHASE STEREOCONTROLLED GLYCOSIDATION HANESSIAN STEPHEN (CA) 1995-02-02 WO disclosed
WO-1995003316-A2 SOLUTION AND SOLID PHASE STEREOCONTROLLED GLYCOSIDATION HANESSIAN STEPHEN (CA) 1995-02-02 WO disclosed
WO-1994026715-A1 AMIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1994-11-24 WO disclosed
WO-1990015058-A1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY THE UPJOHN COMPANY (US) 1990-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267312-A1 AMINO BENZOTHIAZOLE COMPOUNDS FOR TREATMENT OF ANTIBIOTIC RESISTANT BACTERIA BCAT2, BCAT1, ABAT EHMT2 3290/4885EHMT1 3251/4885APOBEC3G 4429/4885
US-12570647-B2 Amino benzothiazole compounds for treatment of antibiotic resistant bacteria BCAT1, BCAT2, IL4I1 EHMT2 3055/4885EHMT1 1839/4885APOBEC3G 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.